Agilent Technologies
About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Employees: 17,900
0
Funds holding %
of 7,457 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
18% more call options, than puts
Call options by funds: $138M | Put options by funds: $116M
13% more funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 9 (+1) [Q1 2025]
2.65% less ownership
Funds ownership: 88.29% [Q4 2024] → 85.64% (-2.65%) [Q1 2025]
7% less funds holding
Funds holding: 1,060 [Q4 2024] → 981 (-79) [Q1 2025]
16% less capital invested
Capital invested by funds: $33.9B [Q4 2024] → $28.5B (-$5.34B) [Q1 2025]
18% less repeat investments, than reductions
Existing positions increased: 323 | Existing positions reduced: 393
34% less first-time investments, than exits
New positions opened: 92 | Existing positions closed: 139
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$115
1%
upside
Avg. target
$131
15%
upside
High target
$159
40%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Jefferies Brandon Couillard 8% 1-year accuracy 2 / 25 met price target | 2%upside $116 | Hold Maintained | 21 Apr 2025 |
Wells Fargo Brandon Couillard 8% 1-year accuracy 2 / 25 met price target | 19%upside $135 | Overweight Maintained | 17 Apr 2025 |
Barclays Luke Sergott 29% 1-year accuracy 18 / 63 met price target | 1%upside $115 | Equal-Weight Maintained | 10 Apr 2025 |
Baird Catherine Schulte 11% 1-year accuracy 2 / 18 met price target | 40%upside $159 | Outperform Maintained | 27 Feb 2025 |
Financial journalist opinion
Based on 8 articles about A published over the past 30 days
Neutral
Business Wire
2 days ago
Agilent to Participate in Jefferies Global Healthcare Conference
SANTA CLARA, Calif--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies Global Healthcare Conference at 10:30 a.m. Eastern on Wednesday, June 4, 2025, in New York City. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in anal.
Positive
Seeking Alpha
1 week ago
Scale Has Its Advantages: 3 A-Rated REIT Monopolies
Scale is a critical competitive advantage for companies, enabling them to expand, attract capital, and achieve strong market positions, as seen with Realty Income, Prologis, and Public Storage. Realty Income leverages its scale and diversification to maintain high occupancy rates and strong financial performance, boasting a fortress balance sheet and impressive dividend growth. Prologis excels with its vast warehouse portfolio, robust development pipeline, and strategic expansion into data centers, supported by a strong balance sheet and high earnings growth.
Positive
Zacks Investment Research
2 weeks ago
Will Agilent (A) Beat Estimates Again in Its Next Earnings Report?
Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neutral
Business Wire
2 weeks ago
Agilent Unveils Transformative Seahorse XF Flex Analyzer: Revolutionizing 3D Tissue and Organoid Research
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced release of the new Seahorse XF Flex Analyzer, a high-performance, 24-well system designed to expand real-time metabolic analysis into optimized 3D tissue and organoid workflows, along with dedicated consumables and kit. Metabolism is vital for cellular functions, driving energy production and essential processes such as biosynthesis, adaptation, redox balance, mitochondrial function, and cell fate decision.
Positive
Zacks Investment Research
2 weeks ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Positive
Seeking Alpha
3 weeks ago
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures.
Neutral
GlobeNewsWire
3 weeks ago
Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission
LEWISVILLE, Ark., April 24, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture (“JV”) between Standard Lithium Ltd.
Neutral
Business Wire
3 weeks ago
Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions t.
Neutral
Business Wire
1 month ago
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced.
Positive
Zacks Investment Research
1 month ago
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Charts implemented using Lightweight Charts™